Ignite Creation Date:
2024-05-06 @ 1:35 PM
Last Modification Date:
2024-10-26 @ 1:16 PM
Study NCT ID:
NCT04062565
Status:
UNKNOWN
Last Update Posted:
2019-08-20
First Post:
2019-03-29
Brief Title:
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
Sponsor:
University of Arizona
Organization:
University of Arizona
Study Overview
Official Title:
A Prospective Trial to Evaluate Up-front Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Patients With Advanced Pulmonary Arterial Hypertension IIR-3810
Status:
UNKNOWN
Status Verified Date:
2019-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension PAH by using a combination of two drugs Treprostinil and Riociquat versus Treprostinil alone
Detailed Description:
The purpose of this study is to evaluate the combined effect of parenteral treprostinil TRE and riociguat RIO versus parenteral TRE alone on right ventricular RV-pulmonary artery PA interaction RVPA coupling and global RV function in patients with advanced pulmonary arterial hypertension PAH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None